Kenneth Ecker
DSF Essential Tremor Scientific Advisory Board
Ken Ecker, PharmD
Vice President, Medical Affairs | Rare Disease, Neurology & Oncology
Ken Ecker is an accomplished executive global leader in medical affairs with over 25 years of experience driving scientific strategy, clinical innovation, and cross-functional collaboration within the pharmaceutical industry. With deep expertise in rare diseases, neurology, and oncology, Ken has led global medical teams at both established companies and startups, guiding product launches, life cycle management, and evidence generation across diverse markets.
Currently serving as Vice President of Medical Affairs at Rare Disease Pharmaceutical Company Ken oversees a team of twenty one MSLs and two Medical Directors supporting therapeutic areas including Duchenne Muscular Dystrophy (DMD), Lambert-Eaton Myasthenic Syndrome (LEMS), and epilepsy. He manages a $10 Million dollar budget across multiple portfolios and spearheads global initiatives such as investigator-initiated studies, CME development, and KOL engagement across North America and Europe.
Throughout his career, Ken has built high-performing medical affairs infrastructures, developed global training programs, and introduced cutting-edge digital platforms for scientific communication. His leadership has resulted in significant expansions in market reach, scientific collaboration, and regulatory advancement. Prior to Catalyst, he held senior roles at Grifols, XenoPort, Boehringer Ingelheim, and others.
Ken holds a Doctor of Pharmacy (PharmD) degree from the University of Florida and a Bachelor of Science in Pharmacy from St. John’s University. He is a licensed pharmacist in Florida and New York and has contributed to peer-reviewed publications in rare diseases.
Vice President, Medical Affairs | Rare Disease, Neurology & Oncology
Ken Ecker is an accomplished executive global leader in medical affairs with over 25 years of experience driving scientific strategy, clinical innovation, and cross-functional collaboration within the pharmaceutical industry. With deep expertise in rare diseases, neurology, and oncology, Ken has led global medical teams at both established companies and startups, guiding product launches, life cycle management, and evidence generation across diverse markets.
Currently serving as Vice President of Medical Affairs at Rare Disease Pharmaceutical Company Ken oversees a team of twenty one MSLs and two Medical Directors supporting therapeutic areas including Duchenne Muscular Dystrophy (DMD), Lambert-Eaton Myasthenic Syndrome (LEMS), and epilepsy. He manages a $10 Million dollar budget across multiple portfolios and spearheads global initiatives such as investigator-initiated studies, CME development, and KOL engagement across North America and Europe.
Throughout his career, Ken has built high-performing medical affairs infrastructures, developed global training programs, and introduced cutting-edge digital platforms for scientific communication. His leadership has resulted in significant expansions in market reach, scientific collaboration, and regulatory advancement. Prior to Catalyst, he held senior roles at Grifols, XenoPort, Boehringer Ingelheim, and others.
Ken holds a Doctor of Pharmacy (PharmD) degree from the University of Florida and a Bachelor of Science in Pharmacy from St. John’s University. He is a licensed pharmacist in Florida and New York and has contributed to peer-reviewed publications in rare diseases.
